商品名：Slentrol
Dirlotapide is used to produce weight loss in dogs. It is related to another medication used for obesity in dogs, mitratapide (Yarvitan), which is approved in Europe. Dirlotapide is an inhibitor of the microsomal triglyceride transfer protein (MTP). The inhibition is selective, and the liver form of MTP is not affected in Precautionary Information Adverse Reactions and Side Effects Adverse effects have not been reported in animals. However, bleeding problems are expected in animals prone to coagulopathies or receiving other anticoagulants. Contraindications and Precautions Do not use in animals with bleeding problems. Drug Interactions Aspirin may potentiate effects. Dirlotapide 247 D dogs. Inhibition of this enzyme reduces the ability of intestinal enterocytes to process triglycerides by
Dirlotapide is used in the management of obesity in dogs. During the treatment protocol, there is a consistent weight loss (approximately 3% per month) that is primarily fat tissue, not lean tissue. Overall, during the entire treatment period it may result in weight loss of 18%-22% of body weight, but response can vary among individual dogs. Dirlotapide should not be used without instituting the proper protocol as outlined by the sponsor. It should be used in an overall weight management program, which also includes appropriate dietary changes. Before using to treat overweight or obesity, rule out other diseases such as hypothyroidism or hyperadrenocorticism.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
執行前必須核對實際產品、濃度、批次標示、所在法域與目前供應狀態。 必須由獸醫確認為合適的犬隻肥胖管理個案，排除肝病與未控制的基礎疾病，並建立體重、食慾、臨床症狀與實驗室追蹤計畫。 在交互作用未逐對完成來源審核前，不得把空清單解讀為無交互作用。
DRUGAPI 劑量審查引用的獸醫官方標示（各標示只適用於其產品、物種與法域，不可互換）
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。